Bioline Rx Ltd ADR (BLRX) concluded trading on Wednesday at a closing price of $0.11, with 13.75 million shares of worth about $1.51 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -86.22% during that period and on January 29, 2025 the price saw a loss of about -3.57%. Currently the company’s common shares owned by public are about 146.09M shares, out of which, 145.28M shares are available for trading.
Stock saw a price change of -5.39% in past 5 days and over the past one month there was a price change of -52.97%. Year-to-date (YTD), BLRX shares are showing a performance of -50.75% which decreased to -90.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.08 but also hit the highest price of $1.44 during that period. The average intraday trading volume for Bioline Rx Ltd ADR shares is 7.52 million. The stock is currently trading -27.61% below its 20-day simple moving average (SMA20), while that difference is down -54.45% for SMA50 and it goes to -79.97% lower than SMA200.
Bioline Rx Ltd ADR (NASDAQ: BLRX) currently have 146.09M outstanding shares and institutions hold larger chunk of about 2.28% of that.
The stock has a current market capitalization of $15.40M and its 3Y-monthly beta is at 1.40. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 1.37 while making debt-to-equity ratio of 3.48. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BLRX, volatility over the week remained 14.96% while standing at 19.28% over the month.
Stock’s fiscal year EPS is expected to rise by 91.44% while it is estimated to decrease by -8.69% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on May 18, 2017 offering a Buy rating for the stock and assigned a target price range of between $1 and $3 to it. Coverage by Rodman & Renshaw stated Bioline Rx Ltd ADR (BLRX) stock as a Buy in their note to investors on February 13, 2017, suggesting a price target of $3 for the stock. On August 12, 2016, Maxim Group Downgrade their recommendations, while on August 17, 2015, Maxim Group Reiterated their ratings for the stock with a price target of $4. Stock get a Buy rating from ROTH Capital on July 27, 2015.
